Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
With a market cap of 250.63B, Merck(MRK) trades at $101.00. The stock has a price-to-earnings ratio of 12.93 and currently yields dividends of 3.3%.
As of 2025-11-24, Merck(MRK) stock has fluctuated between $98.70 and $101.89. The current price stands at $101.00, placing the stock +2.3% above today's low and -0.9% off the high.
The Merck(MRK)'s current trading volume is 8.25M, compared to an average daily volume of 16.56M.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
MRK News
Merck (MRK) announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology Annual Meeting and Expositi...
Wells Fargo upgraded Merck (MRK) to Overweight from Equal Weight with a price target of $125, up from $90. Following recent business development, pipeline progr...
Merck (MRK) is making waves this week as the company announced a series of meaningful regulatory and clinical updates. Highlights include new FDA and European a...
Analyst ratings
62%
of 29 ratingsMore MRK News
Schwab US Dividend Equity ETF ( $SCHD ) has risen by 0.37% in the past week. It has experienced a 5-day net outflow of $54.69 million. This is due, in part, to...
(RTTNews) - Merck & Co Inc. (MRK) has been notified that Tutanota LLC has commenced an unsolicited mini-tender offer, dated November 10, 2025, to purchase up to...
Shares of Merck & Company, Inc. (NASDAQ:MRK) are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer....
The pharmaceutical giant's post-Keytruda plans continue to take shape. Over the past two years, Merck (MRK +0.06%) has faced several challenges, resulting in a...
Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen...
Merck (MRK) announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of d...
Merck (MRK) announced that the European Commission has approved a new subcutaneous, or under the skin, route of administration and a new pharmaceutical form of...